Use of anti-TNF Etanercept in paediatric patients with autoimmune disease and ocular involvement: the Parma experience by Rossi, M et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Pediatric Rheumatology
Open Access Poster presentation
Use of anti-TNF Etanercept in paediatric patients with 
autoimmune disease and ocular involvement: the Parma 
experience
M Rossi*, S Gonzales, J Orsoni, L Zavota, A De Fanti and GC Izzi
Address: University Hospital, Parma, Italy
* Corresponding author    
Objective
Previous studies showed that treatment with anti-TNF
Etanercept in patients with autoimmune disease such as
juvenile rheumatoid arthritis (JRA) or Behçet's Disease
provides clinical improvement and efficacy. We evaluated
the effectiveness of anti-TNF therapy on ocular involve-
ment and its toxicity.
Methods
6 Patients with autoimmune disease, followed in our Cen-
tre, have been evaluated since January 2007 until May
2008; 4 of them were treated with Etanercept since the
beginning of the study, 1 for 5 months and 1 for 3
months. In all patients Etanercept was added to a polip-
harmacological immunomodulating therapy scheme,
including Cyclosporine, Methotrexate and steroids. Safety
was assessed by monitoring rates of serious adverse events
(SAEs), effects on hepatic and renal function and serious
infections rates. Efficacy on ocular involvement was
assessed by monitoring and measuring inflammatory
relapses.
Results
All patients studied received complete efficacy assess-
ments. During the study period we observed neither SAEs
nor serious infectious diseases. All patients enrolled in the
study didn't show any effect on hepatic and renal function
due to Etanercept's use. Concerning the effectiveness of
Etanercept on ocular involvement, we observed only 1
inflamatory relapse in 1 patient, at the beginning of anti-
TNF treatment.
Conclusion
In our study Etanercept showes an acceptable safety pro-
file on hepatic and renal function and on the risk of seri-
ous infections in children with ocular involvement in
autoimmune diseases; moreover, it provides significant
improvement in disease's ocular manifestations.
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